Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Urse

Orthopaedic Surgery Dayton, OH Doctor of Osteopathy

NPI 1619979689 CMS profile 163603

4160 Little York Rd, Ste. 10, Dayton, OH 45414

Open in the dashboard

General payments

$10,775

103 records reported · program years 2019–2025

Research payments

$5,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Urse of Dayton, OH is reported in the CMS Open Payments database as having received $10,775 across 103 general payments and $5,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $457 9
2024 General $459 12
2024 Research $5,000 1
2023 General $1,135 20
2022 General $2,111 15
2021 General $554 8
2020 General $1,372 15
2019 General $4,686 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Urse
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to John Urse were reported at $457. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year John Urse Orthopaedic Surgery median Middle half National median
2019 $4,686 $644 $140–$2,844 $163
2020 $1,372 $312 $75–$1,860 $114
2021 $554 $520 $117–$2,495 $132
2022 $2,111 $598 $128–$2,731 $149
2023 $1,135 $461 $128–$2,264 $160
2024 $459 $497 $134–$2,475 $164
2025 $457 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $4,606 7 payments
  2. CDC Medical LLC $1,934 3 payments
  3. Stryker Corporation $1,651 22 payments
  4. Zimmer Biomet Holdings, Inc. $972 17 payments
  5. Smith+Nephew, Inc. $192 7 payments
  6. Inspire Medical Systems, Inc. $185 5 payments
  7. Conformis, Inc. $152 3 payments
  8. Ethicon US, LLC $129 5 payments
  9. DePuy Synthes Sales Inc. $126 4 payments
  10. Cerapedics, Inc. $106 1 payment
  11. Other $722 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,500 3 payments
  2. Food and Beverage $4,143 95 payments
  3. Education $1,403 3 payments
  4. Travel and Lodging $729 2 payments
Products named General payments · program years 2019–2025
  1. Persona $358 10 payments
  2. MAKO Knees, Hips $253 3 payments
  3. MAKO Knees, Hips $230 6 payments
  4. HOFFMANN $214 1 payment
  5. Comprehensive Shoulder System $195 2 payments
  6. Identity $195 2 payments
  7. INSPIRE $185 5 payments
  8. PANGEA $167 1 payment
  9. mymobility Platform $155 5 payments
  10. None $140 1 payment
  11. Other $4,351 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Episurf Medical, Inc. $5,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

809

Median for Orthopedic Surgery: 203

Drug cost

$13,110

Median for Orthopedic Surgery: $1,433

Branded share of claims

32.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $4,340
Calcipotriene Generic 14 $4,173
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 142 $909
Celecoxib Generic 28 $864
Gabapentin Generic 83 $606
Clindamycin Hcl Generic 105 $483
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 92 $448
Ondansetron Hcl Generic 56 $379
Methylprednisolone Generic 39 $269
Diclofenac Sodium Er Diclofenac Sodium Brand 19 $224

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$141,717

Of which drugs: $4,221

Medicare patients

273

Average age 74

Services billed

1,537

168 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 30%
Chronic kidney disease 26%
Depression 24%
Atrial fibrillation 19%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 87 574 $444

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record